MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis

Wang, Xiaotong; Kong, Fan‐Biao; Mai, Weiyi; Li, Lei; Pang, Li-Ming

doi:10.1155/2016/9421571

Cited by 40 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, we further identified MAGEA12 expression as a novel predictor for the outcome of gastric cancers. Currently, several other prognostic markers in gastric cancer such as such as MUC1 have been validated [16], therefore, here we also proposed that combination of MAGEA12 with other factors may add prognostic and classification information for gastric cancers.…”

Section: Discussionmentioning

confidence: 91%

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Wu¹,

Wang²,

Shen³

2017

neo

View full text Add to dashboard Cite

Melanoma antigen (MAGE) family genes are frequently over-expressed in a subset population of multiple cancers, and serve as idea therapeutic targets; however, their distribution pattern in gastric cancers has not yet been evaluated. In this study, we first performed a cancer outlier profile analysis (COPA) on a series of public gene expression datasets of gastric cancer, and identified MAGEA12 showing a significant outlier expression model reproducibly. We further in silico validated that MAGEA12 outlier over-expression were associated with poor clinical outcome using six microarray datasets from GEO database. We then experimentally detected the MAGEA12 expression in an independent cohort of gastric cancer samples by immunohistochemistry, and showed that over-expression of MAGEA12 in a subset of cancers was associated with later stage and reduced survival; furthermore, MAGEA12 was an independent prognostic factor in an outlier manner. Our results indicate that MAGEA12 is a novel prognostic outlier gene in gastric cancers and patterns of MAGE expression may inform individualized targeted immunotherapies.

show abstract

Section: Discussionmentioning

confidence: 91%

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Wu¹,

Wang²,

Shen³

2017

neo

View full text Add to dashboard Cite

show abstract

“…Furthermore, MUC1 in tumor cells has been shown to be aberrantly glycosylated, which results in overexpression of several novel tumor-associated carbohydrate structures that can serve as a possible prognostic marker or therapeutic target. A recent meta-analysis of ten translational studies demonstrate that MUC1 immunohistochemical expression is highly correlated with intestinal histology, vascular invasion, nodal metastasis, and decreased survival in gastric cancer patients [37].…”

Section: Discussionmentioning

confidence: 99%

Molecular Classification of Gastric Cancer among Alaska Native People

Martinson

Mallari

Richter

et al. 2020

Cancers

View full text Add to dashboard Cite

Gastric cancer is an aggressive and heterogeneous malignancy that often varies in presentation and disease among racial and ethnic groups. The Alaska Native (AN) people have the highest incidence and mortality rates of gastric cancer in North America. This study examines molecular markers in solid tumor samples from eighty-five AN gastric adenocarcinoma patients using next-generation sequencing, immunohistochemistry, and in situ hybridization analysis. AN patients have a low mutation burden with fewer somatic gene mutations in their tumors compared to other populations, with the most common mutation being TP53. Epstein-Barr virus (EBV) was associated with 20% of AN gastric cancers, which is higher than the world average of 10%. The inflammation marker, cyclooxygenase-2 (COX-2), is highly expressed in patients with the lowest survival rates. Mismatch repair deficiency was present in 10% of AN patients and was associated with patients who were female, 50 years or older, gene mutations, and tumors in the distal stomach. Program death-ligand 1 (PD-L1) was expressed in 14% of AN patients who were more likely to have MMR deficiency, EBV-associated gastric cancers, and mutations in the PIK3CA gene, all of which have been linked to clinical response to PD-1 inhibitors. These studies suggest a portion of AN gastric cancer patients could be candidates for immunotherapy. Overall, this study highlights future avenues of investigation for clinical and translational studies, so that we can improve early detection and develop more effective treatments for AN patients.

show abstract

“…In this study, p53 and Ki-67 markers were not found to be associated with tumor recurrence (15) . Other markers are used to understand tumor biological behavior, e.g., mucin expression, through which subclassification of gastric cancer in phenotypes was established (2,7,14,19,49,64,66,69) . Thus, gastric tumors may express mucin phenotypes of gastric, intestinal, and mixed intestinal and gastric, or indeterminate types (10,50) .…”

Section: Discussionmentioning

confidence: 99%

Characterization of the Mucin Phenotype Can Predict Gastric Cancer Recurrence After Endoscopic Mucosal Resection

Hondo

Kishi

Safatle‐Ribeiro

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Endoscopic mucosal resection is still considered an accepted treatment for early gastric cancer for selected cases. Histopathologic criteria for curative endoscopic resection are intramucosal well-differentiated adenocarcinoma, lateral and deep margins free of tumor, no histological ulceration, and no venous or lymphatic embolism. A 5% local recurrence rate has been described even when all the above-mentioned criteria are met. On the other hand, antigen expression by tumoral cells has been related to the biological behavior of several tumors. Objective -To evaluate whether early gastric cancer mucin immunoexpression, p53 and Ki-67, can predict recurrence after endoscopic mucosal resection, even when standard histopathologic criteria for curative measures have been attempted. Methods -Twenty-two patients with early gastric cancer were considered to have been completely resected by endoscopic mucosal resection. Local recurrence occurred in 5/22 (22.7%). Immunohistochemical study was possible in 18 (81.8%) resected specimens. Patients were divided in two groups: those with and those without local recurrence. They were compared across demographic, endoscopic, histologic data, and immunohistochemical factors for MUC2, MUC5a, CD10, p53, and Ki-67. Results -Mucin immunoexpression allowed a reclassification of gastric adenocarcinoma in intestinal (10), gastric (2), mixed (4), and null phenotypes (2). Mixed phenotype (positive for both MUC2 and MUC5a) was found in 80% of cases in the local recurrence group, while the intestinal type (positive MUC2 and negative MUC5a) was found in 76.9% of cases without local recurrence (P=0.004). Other observed features did not correlate with neoplastic recurrence. Conclusion -The mixed phenotype of early gastric adenocarcinoma is associated with a higher probability of local recurrence after endoscopic mucosal resection.HEADINGS -Stomach neoplasms. Endoscopic mucosal resection. Gastric mucins.

show abstract

MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis

Cited by 40 publications

References 36 publications

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Molecular Classification of Gastric Cancer among Alaska Native People

Characterization of the Mucin Phenotype Can Predict Gastric Cancer Recurrence After Endoscopic Mucosal Resection

Contact Info

Product

Resources

About